CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+14.98%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$787M
AUM Growth
+$787M
(+53%)
Cap. Flow
+$228M
Cap. Flow
% of AUM
29.03%
Top 10 Holdings %
Top 10 Hldgs %
30.43%
Holding
459
New
34
Increased
332
Reduced
39
Closed
19
Top Buys
| 1 |
Microsoft
MSFT
|
$18.2M |
| 2 |
NVIDIA
NVDA
|
$11.9M |
| 3 |
Netflix
NFLX
|
$9.94M |
| 4 |
Amazon
AMZN
|
$7.89M |
| 5 |
Meta Platforms (Facebook)
META
|
$7.84M |
Top Sells
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
$3.64M |
| 2 |
Alibaba
BABA
|
$2.59M |
| 3 |
XYZ
Block, Inc.
XYZ
|
$2.4M |
| 4 |
Intel
INTC
|
$2.07M |
| 5 |
Coca-Cola
KO
|
$1.91M |
Sector Composition
| 1 | Technology | 37.36% |
| 2 | Healthcare | 29.98% |
| 3 | Consumer Discretionary | 13.6% |
| 4 | Communication Services | 8.97% |
| 5 | Financials | 3.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Verisk Analytics
VRSK
$37B
| $153K | 0.02% |
647
+358
| +124% | +$84.4K |
|
327
Kiniksa Pharmaceuticals
KNSA
$2.54B
| $152K | 0.02% |
7,708
+3,611
| +88% | +$71.2K |
|
328
Baker Hughes
BKR
$44.7B
| $151K | 0.02% |
4,515
+2,530
| +127% | +$84.8K |
|
329
Wave Life Sciences
WVE
$1.53B
| $145K | 0.02% |
23,473
+12,017
| +105% | +$74.1K |
|
330
Allogene Therapeutics
ALLO
$249M
| $145K | 0.02% |
32,348
+12,881
| +66% | +$57.6K |
|
331
Estee Lauder
EL
$32.7B
| $144K | 0.02% |
936
+837
| +845% | +$129K |
|
332
Coca-Cola Europacific Partners
CCEP
$39.7B
| $144K | 0.02% |
2,060
+1,151
| +127% | +$80.5K |
|
333
ON Semiconductor
ON
$20B
| $142K | 0.02% |
1,927
-4,929
| -72% | -$363K |
|
334
Zymeworks
ZYME
$1.06B
| $141K | 0.02% |
13,444
+5,344
| +66% | +$56.2K |
|
335
Cabaletta Bio
CABA
$133M
| $140K | 0.02% |
8,206
+3,244
| +65% | +$55.3K |
|
336
Enliven Therapeutics
ELVN
$1.24B
| $140K | 0.02% |
7,952
+3,189
| +67% | +$56.1K |
|
337
Aurinia Pharmaceuticals
AUPH
$1.54B
| $139K | 0.02% |
27,802
+11,189
| +67% | +$56.1K |
|
338
Nurix Therapeutics
NRIX
$696M
| $138K | 0.02% |
9,404
+3,793
| +68% | +$55.8K |
|
339
Y-mAbs Therapeutics
YMAB
$389M
| $136K | 0.02% |
8,390
+3,340
| +66% | +$54.3K |
|
|
ANSS
340
DELISTED
Ansys
ANSS
| $136K | 0.02% |
392
+218
| +125% | +$75.7K |
|
341
Xcel Energy
XEL
$42.7B
| $136K | 0.02% |
2,504
+1,401
| +127% | +$76K |
|
342
Cogent Biosciences
COGT
$1.68B
| $134K | 0.02% |
19,950
+9,989
| +100% | +$67.1K |
|
343
CureVac
CVAC
$1.21B
| $130K | 0.02% |
43,019
+17,132
| +66% | +$51.9K |
|
344
Savara
SVRA
$572M
| $130K | 0.02% |
26,035
+10,381
| +66% | +$51.7K |
|
345
Zscaler
ZS
$42.7B
| $129K | 0.02% |
669
+375
| +128% | +$72.2K |
|
346
GlobalFoundries
GFS
$18.4B
| $129K | 0.02% |
2,471
+1,391
| +129% | +$72.5K |
|
347
Novavax
NVAX
$1.23B
| $128K | 0.02% |
26,878
+13,135
| +96% | +$62.8K |
|
|
SLRN
348
DELISTED
ACELYRIN
SLRN
| $126K | 0.02% |
18,718
+7,459
| +66% | +$50.3K |
|
349
SIGA Technologies
SIGA
$618M
| $125K | 0.02% |
13,660
+5,435
| +66% | +$49.6K |
|
|
CNTA
350
Centessa Pharmaceuticals
CNTA
$2.32B
| $122K | 0.02% |
10,817
+4,423
| +69% | +$50K |
|